Reading Time:

6 minutes

A New Catheter that Fights Bacteria Films

Biofilms are dangerous colonies of bacteria forming inside medical devices, especially catheters. “About 95% of urinary tract infections (UTIs) are associated with the use of a urinary catheter, with an average cost of treatment of $44,043 for each hospital stay from CAUTI and a negative impact on patient recovery and quality of life.”1

Urinary Tract Infections are the most common infections caused by biofilms. “More than 75% of hospital-acquired or nosocomial urinary tract infections are initiated by urinary catheters, which are used during the treatment of 15–25% of hospitalized patients. Among other purposes, urinary catheters are primarily used for draining urine after surgeries and for urinary incontinence. During catheter-associated urinary tract infections, bacteria travel up to the bladder and cause infection. A major cause of catheter-associated urinary tract infection is attributed to the use of non-ideal materials in the fabrication of urinary catheters. Such materials allow for the colonization of microorganisms, leading to bacteriuria and infection, depending on the severity of symptoms. The ideal urinary catheter is made out of materials that are biocompatible, antimicrobial, and antifouling.”2

The Evolution of Catheters

“Urinary catheters have been used since the third century B.C., by the Greeks, Egyptians and Chinese, but the first malleable urinary catheter on record was only made in 1779 by a goldsmith, Bernard. Some of the first materials used to make urinary catheters were copper, tin, bronze, gold, lead, papyrus, onion stems, dried reeds, and palm leaves. In recent times, materials such as gum-elastic, plastic (polyvinyl chloride, PVC), polyurethanes, silicone and latex rubbers have been used for their superior malleability. These materials have been developed over the years to include most of the characteristics desirable in a catheter: high tensile strength, soft and pliable, inherently chemical resistant, biocompatible and able to meet flow requirements while maintaining a minimally invasive circumference or French profile.”3

How to Prevent Bacteria Films

“The current approach for preventing catheter-associated infections has been either systemic antibiotic prophylaxis or antimicrobial coating of the device surface to reduce the concentration of bacteria. While antimicrobial agents can suppress UTI temporarily (for only days), colonization and infection of the urinary tract with resistant bacteria will eventually occur. Once a biofilm forms, the biofilm-embedded bacteria become protected from antimicrobial agents. In fact, when treated with antibiotics, these biofilms are not fully eradicated and begin to harbor antibiotic-resistant bacteria, which may compromise the effectiveness of these agents for even non-biofilm-mediated infections.”4

Patients currently using indwelling catheters oftentimes encounter blockage issues from these bacterial biofilms, as well as a propensity to acquire a urinary tract infection because these bacteria can make their way into the urinary tract.

“For the millions of people forced to rely on a plastic tube to eliminate their urine, developing an infection is nearly a 100 percent guarantee after just four weeks. But with the help of a little bubble-blowing, biomedical engineers hope to bring relief to urethras everywhere.”5

New Catheter Design that Fights Biofilms

“About half of the time, the interior of long-term urinary catheters become plagued by biofilms, structures formed by colonies of bacteria that are extremely difficult to kill. Once established, it is only a matter of time before the biofilm becomes a welcoming host for other, more dangerous bacteria or begins to choke urine drainage, causing leakage, or even trauma to the patient’s body.”6

However, scientists have developed a clever catheter design to prevent biofilms from interrupting healthy catheterizations. The new catheter uses a separate channel parallel to the drainage area. The specialist can inflate it with saline solutions or air. This causes the drainage area to stretch and deform, forcing the lodged biofilm out of position.

A team of Duke University scientists is in trial phases of a new catheter that is able to eliminate bacterial biofilms inside the drain tube. “Duke University engineers have developed a new urinary catheter design that can eliminate nearly all of the hard-to-kill biofilm from the catheter walls. Instead of focusing on expensive antibacterial coatings, the researchers use physical deformation to knock the infectious film from its moorings.”7

Bacterial colonies produce this biofilm to protect themselves from outside forces, sort of like a town carapace. Introducing air or saline into the channel that runs parallel to it, and thus deforming the inner wall where the biofilm grows, the bacterial town carapace shakes, breaks and/or gets compromised. When urine flows through, it is flushed along with the urine.

“The biofilm mode of growth has been implicated in the majority of human bacterial infections. In the urinary tract, notable biofilm-associated infections include prostatitis, chronic cystitis, struvite urolithiasis, and catheter-associated infections.”8

Before this breakthrough approach, most manufacturers focused on creating anti-bacterial films to fight the bacterial wall, with minor success. Catheter-induced urinary tract infections are still the number one hospital-acquired infections in the United States. The aforementioned mechanical way to eliminate these bacterial biofilms is much more effective, and bacteria cannot develop a defense. Additionally, patients who self-catheterize will probably be able to perform this at home.

Bacteria Film Infection Risk and Treatment

The high risk of contracting a urinary tract infection due to the solidification of biofilms is the basis for the creation of this bacterial biofilm-destroying catheter. These bacterial coatings cause complications to the healthcare practitioner and patients, especially if they are disabled or elderly.

“Because treatment of asymptomatic bacteriuria in adults is generally unlikely to confer clinical benefit, antibiotics are recommended only for pregnant women and for individuals who are about to undergo urological procedures. Indeed, treatment of asymptomatic bacteriuria in diabetic women was found to incur harm, because the treated group had a higher incidence of adverse antimicrobial reactions yet had the same incidence of symptomatic UTI as did the untreated group.”9

The scientific community has dedicated several funds and researching to developing bacteria-fighting throughout the years. Not to mention the post-infection healthcare costs, particularly in recurring cases of UTI. 

Before this catheter, patients and healthcare practitioners had to replace the catheter due to the blockages derived from the accumulation of bacterial biofilm layers. Interrupting this accumulation of bacteria reduces catheter-induced urinary tract infections and provides comfort, safety, assurance and a higher quality of life to patients who require catheterizations for their particular condition.

“Biofilm removal from biomaterials is of fundamental importance and is especially relevant when considering the problematic and deleterious impact of biofilm infections on the inner surfaces of urinary catheters. Catheter-associated urinary tract infections are the most common cause of hospital-acquired infections and there are over 30 million Foley urinary catheters used annually in the USA.”10

However, the biofilm-breaking catheter is not finished, it is still under development since bacteria still grows in microscopic crevices or imperfections along the catheter. Currently, the scientific community aims to create a catheter with several inflation chambers to segregate and dislodge biofilm throughout the catheter walls.

“It is hoped that further advances in medical technology will allow modification of catheterization procedures, duration and need for catheterization, and provide improvements in the design of catheter urinary drainage systems. Studies have demonstrated that the internal luminal route of catheter-associated infections can be almost completely negated, at least for a short time, by the use of a strictly maintained sterile closed drainage system, with the possible addition of a bacterial barrier or hurdle. 

The design of such a device or mechanism to stop the periurethral route would be very helpful. Biomaterial research is an exploding new science, and research must continue with these new materials in respect to mucosal biocompatibility and effectiveness in reducing bacterial biofilm attachment.”11

The medical community expects that upcoming biomaterial will ultimately decrease bacterial adherence and biofilm accumulation to lower the rate of catheter-associated infection.

 

References:

(1, 4) Micropatterned Surfaces for Reducing the Risk of Catheter-Associated Urinary Tract Infection. Reddy, S., Chung, K., McDaniel, C., Darouiche, R., Landman, J., & Brennan, A. Journal of Endourology. 2011. https://pdfs.semanticscholar.org/a9ae/6b4ed331f43e8eea7ae36810cf8159c6b910.pdf

(2, 3) A Review of the Recent Advances in Antimicrobial Coatings for Urinary Catheters. Singha, P., Locklin, J., & Handa, H. Acta Biomaterialia. 2017. https://www.sciencedirect.com/science/article/pii/S1742706116306663?via%3Dihub

(5, 6, 7) Catheter Innovation Destroys Dangerous Biofilms. Kingery, K. Duke University: Pratt School of Engineering. 2014. https://pratt.duke.edu/about/news/catheter-innovation-destroys-dangerous-biofilms

(8) The Development Of Bacterial Biofilm on Indwelling Catheters. Morris, N., Stickler, D., & McLean, R. World Journal of Urology. 1999. https://www.researchgate.net/publication/12661127_The_development_of_bacterial_biofilms_on_indwelling_catheters

(9) Inappropriate Treatment of Catheter-Associated Asymptomatic Bacteriuria in a Tertiary Care Hospital. Trautner, B., Cope, M., Cevallos, M., Cadle, R., Darouiche, R., & Musher, D. Clinical Infectious Disease. 2009. https://academic.oup.com/cid/article/48/9/1182/407035

(10) Urinary catheter capable of repeated on-demand removal of infectious biofilms via active deformation. Levering, V., Cao, C., Shivapooja, P., Levinson, H., Zhao, X., & López, Gabriel. Biomaterials. 2016. https://www.sciencedirect.com/science/article/pii/S0142961215008807?via%3Dihub 

(11) Bacterial biofilms and catheters: A key to understanding bacterial strategies in catheter-associated urinary tract infection. Nickel, J., & Costerton, J. The Canadian Journal of Infectious Diseases. 1992. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3298070/

 

María Laura Márquez
13 October, 2018

Written by

María Laura Márquez, general doctor graduated from The University of Oriente in 2018, Venezuela. My interests in the world of medicine and science, are focused on surgery and its breakthroughs. Nowadays I practice my profession...read more:

9 thoughts on “A New Catheter that Fights Bacteria Films

  1. ciclosporin, also spelled cyclosporine and cyclosporin, is a calcineurin inhibitor, used as an immunosuppressant medication. it is a natural product. it is taken by mouth or by injection into a vein for rheumatoid arthritis, psoriasis, crohn’s disease, nephrotic syndrome, and in organ transplants to prevent rejection. it is also used as eye drops for keratoconjunctivitis sicca (dry eyes).

    common side effects include high blood pressure, headache, kidney problems, increased hair growth, and vomiting. other severe side effects include an increased risk of infection, liver problems, and an increased risk of lymphoma. blood levels of the medication should be checked to decrease the risk of side effects. use during pregnancy may result in preterm birth; however, ciclosporin does not appear to cause birth defects.

    ciclosporin is believed to work by decreasing the function of lymphocytes. it does this by forming a complex with cyclophilin to block the phosphatase activity of calcineurin, which in turn decreases the production of inflammatory cytokines by t-lymphocytes.

    ciclosporin was isolated in 1971 from the fungus tolypocladium inflatum and came into medical use in 1983. it is on the world health organization’s list of essential medicines, the safest and most effective medicines needed in a health system. in 2017, it was the 248th most commonly prescribed medication in the united states, with more than one million prescriptions that year.

    medical uses
    ciclosporin is approved by the fda to treat and prevent graft-versus-host disease in bone marrow transplantation and to prevent rejection of kidney, heart, and liver transplants. it is also approved in the us for treating of rheumatoid arthritis and psoriasis, persistent nummular keratitis following adenoviral keratoconjunctivitis, and as eye drops for treating dry eyes caused by sj?gren’s syndrome and meibomian gland dysfunction.

    in addition to these indications, ciclosporin is also used in severe atopic dermatitis, kimura disease, pyoderma gangrenosum, chronic hives, acute systemic mastocytosis, and posterior or intermediate uveitis with noninfective cause.[citation needed] it is also used, albeit infrequently, in severe rheumatoid arthritis and related diseases.[citation needed]

    ciclosporin has also been used in people with acute severe ulcerative colitis and hives that do not respond to treatment with steroids.

  2. selamectin (trade names, revolt manufactured by aurora pharmaceutical & revolution manufactured by zoetis ) is a topical parasiticide and anthelminthic used on dogs and cats. it treats and prevents infections of heartworms, fleas, ear mites, sarcoptic mange (scabies), and certain types of ticks in dogs, and prevents heartworms, fleas, ear mites, hookworms, and roundworms in cats. it is structurally related to ivermectin and milbemycin. selamectin is not approved for human use.

    usage
    the drug is applied topically. it is isopropyl alcohol based, packaged according to its varying dosage sizes and applied once monthly. it is not miscible in water.

    selamectin disables parasites by activating glutamate-gated chloride channels at muscle synapses. selamectin activates the chloride channel without desensitization, allowing chloride ions to enter the nerve cells and causing neuromuscular paralysis, impaired muscular contraction, and eventual death.

    the substance fights both internal and surface parasitic infection. absorbed into the body through the skin and hair follicles, it travels through the bloodstream, intestines, and sebaceous glands; parasites ingest the drug when they feed on the animal’s blood or secretions.

    selamectin has been found to be safe and effective in a 2003 review.

    selamectin has high safety ratings, with less than 1% of pets displaying side effects[citation needed]. in cases where side-effects do occur, they most often include passing irritation or hair loss at the application site. symptoms beyond these (such as drooling, rapid breathing, lack of coordination, vomiting, or diarrhea) could be due to shock as a result of selamectin killing heartworms or other vulnerable parasites present at high levels in the bloodstreams of dogs.[citation needed] this would be a reaction due to undetected or underestimated infections prior to using the medication, rather than an actual allergic reaction to the drug itself.

Leave a Reply

If you would also like a response sent to your email please add it in the email box below.